Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving virus or bacteriophage
Reexamination Certificate
2006-02-21
2006-02-21
Mosher, Mary E. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving virus or bacteriophage
C435S007100, C435S032000, C436S501000
Reexamination Certificate
active
07001718
ABSTRACT:
The present invention relates to methods of detecting or identifying inhibitors of a Z-DNA binding ligand to Z-DNA, methods of inhibiting the pathogenicity of an infectious agent, antiviral therapies, and compounds that inhibit complex formation between a Z-DNA binding ligand and Z-DNA.
REFERENCES:
patent: 5726050 (1998-03-01), Rich et al.
patent: WO 97/00949 (1997-01-01), None
patent: WO 00/73487 (2000-12-01), None
Herbert et al (Genetica 106:37-47, 1999, abstract only cited).
Inoue et al, BBRC 266:147-151, 1999.
Blaho et al, Journal of Biological Chemistry 262:6062-6068, 1987.
Kim, Y.G. et al., “A Role for Z-DNA Binding in Vaccinia Virus Pathogenesis,”Proc. Natl. Acad. Sci. USA, 100(12):6974-6979 (2003).
Rich, A. et al., “Z-DNA: The Long Road to Biological Function,” Nature Reviews, 4(7):566-572 (2003).
Oh, D.-B., et al., “Z-DNA-Binding Proteins Can Act as Potent Effectors of Gene ExpressionIn Vivo,” Proceedings of the National Academy of Sciences U.S.A., 99(26):16666-16671 (2002).
Kim, Y.-G., et al., “A Role for Z-DNA Binding in Vaccinia Virus Pathogenesis,”Proceedings of the National Academy of Sciences U.S.A., 100(12):6974-6979 (2003).
Behe, M. and Felsenfeld, G., “Effects of Methylation on a Synthetic Polynucleotide: The B-Z Transition in Poly(dG-m5dC) • Poly(dG-m5dC),”Proceedings of the National Academy of Sciences U.S.A., 78:1619-1623 (1981).
Berger, I., et al., “Spectroscopic Characterization of a DNA-Binding Domain, Zα, from the Editing Enzyme, dsRNA Adenosine Deaminase: Evidence for Left-Handed Z-DNA in the Zα-DNA Complex,”Biochemistry, 37:13313-13321 (1998).
Bloom, D.C., et al., “Identification and Characterization of Two Nonessential Regions of the Rabbitpox Virus Genome Involved in Virulence,”Journal of Virology, 65:1530-1542 (1991).
Brandt, T.A. and Jacobs, B.L., “Both Carboxy- and Amino-Terminal Domains of the Vaccinia Virus Interferon Resistance Gene, E3L, Are Required for Pathogenesis in a Mouse Model,”Journal of Virology, 75:850-856 (2001).
Brigido, M.M. and Stollar, B.D., “Two Induced Anti-Z-DNA Monoclonal Antibodies Use VH Gene Segments Related to Those of Anti-DNA Autoantibodies,”The Journal of Immunology, 146:2005-2009 (1991).
Brown, B.A., et al., “The Zα Domain of the Editing Enzyme dsRNA Adenosine Deaminase Binds Left-Handed Z-RNA as Well as Z-DNA,”Proceedings of the National Academy of Sciences U.S.A., 97:13532-13536 (2000).
Enserink, M. And Stone, R., “Dead Virus Walking,”Science, 295:2001-2003 and 2005 (Mar., 2002).
Fu, Y., et al., “Cloning of DLM-1, A Novel Gene that is Up-Regulated in Activated Macrophages, Using RNA Differential Display,”Gene, 240:157-163 (1999).
Herbert, A. and Rich, A., “The Biology of Left-Handed Z-DNA,”The Journal of Biological Chemistry, 271:11595-11598 (1996).
Herbert, A.G. and Rich, A., “A Method to Identify and Characterize Z-DNA Binding Proteins Using a Linear Oligodeoxynucleotide,”Nucleic Acids Research, 21:2669-2672 (1993).
Herbert, A., et al., “A Z-DNA Binding Domain Present in the Human Editing Enzyme, Double-Stranded RNA Adenosine Deaminase,”Proceedings of the National Academy of Sciences U.S.A., 94:8421-8426 (1997).
Herbert, A., et al., “The Zα Domain from Human ADARI Binds to the Z-DNA Conformer of Many Different Sequences,”Nucleic Acids Research, 26:3486-3493 (1998).
Jiang, H., et al., “Potassium Permanganate as anIn SituProbe for B-Z and Z-Z Junctions,”Nucleic Acids Research, 19:6943-6948 (1991).
Kibler, K.V., et al., “Double-Stranded RNA Is a Trigger for Apoptosis in Vaccinia Virus-Infected Cells,”Journal of Virology, 71:1992-2003 (1997).
Kim, J-M., et al., “Analysis of Left-Handed Z-DNA Formation in Short d(CG)ηSequences inEscherichia coliandHalobacterium halobiumPlasmids,”The Journal of Biological Chemistry, 271:9340-9346 (1996).
Kim, Y-G., et al., “Construction of a Z-DNA-Specific Restriction Endonuclease,”Proceedings of the National Academy of Sciences USA, 94:12875-12879 (1997).
Kim, Y-G., et al., “The Interaction Between Z-DNA and the Zab Domain of Double-Stranded RNA Adenosine Deaminase Characterized Using Fusion Nucleases,”The Journal of Biological Chemistry, 274:19081-19086 (1999).
Kim, Y-G., et al., “The Zab Domain of the Human RNA Editing Enzyme ADAR1 Recognizes Z-DNA When Surrounded by B-DNA,”The Journal of Biological Chemistry, 275:26828-26833 (2000).
Liu, J., et al., “Identifying DNA-Binding Sites and Analyzing DNA-Binding Domains Using a Yeast Selection System,”Methods: A Companion to Methods in Enzymology, 5:125-137 (1993).
Qu, X, et al., “Allosteric, Chiral-Selective Drug Binding to DNA,”Proceedings of the National Academy of Sciences U.S.A., 97:12032-12037 (Oct., 2000).
Rich, A., “A Therapy for Smallpox,”CRISP—Computer Retrieval of Informational on Scientific Projects, National Institutes of Health, http://commons.cit.nih.gov (2002) Abstract.
Schade, M., et al., “Structure-Function Analysis of the Z-DNA-Binding Domain Zα of dsRNA Adenosine Deaminase Type I Reveals Similarity to the (α+β) Family of Helix-Turn-Helix Proteins,”The EMBO Journal, 18:470-479 (1999).
Schade, M., et al., “The Solution Structure of the Zα Domain of the Human RNA Editing Enzyme ADAR1 Reveals a Prepositioned Binding Surface for Z-DNA,”Proceedings of the National Academy of Sciences U.S.A., 96:12465-12470 (1999).
Schwartz, T., et al., “Crystal Structure of the Zα Domain of the Human Editing Enzyme ADAR1 Bound to Left-Handed Z-DNA,”Science, 284:1841-1845 (1999).
Schwartz, T., et al., “Proteolytic Dissection of Zab, the Z-DNA-Binding Domain of Human ADAR1,”The Journal of Biological Chemistry, 274:2899-2906 (1999).
Schwartz, T., et al., “Structure of the DLM-1-Z-DNA Complex Reveals a Conserved Family of Z-DNA-Binding Proteins,”Nature Structural Biology, 8:761-765 (2001).
Schors, S.T., et al., “Role of the Vaccinia Virus E3L and K3L Gene Products in Rescue of VSV and EMCV from the Effects of IFN-α, ”Journal of Interferon and Cytokine Research, 18:721-729 (1998).
Uvarova, E.A. and Shchelkunov, S.N., “Species-Specific Differences in the Structure of Orthopoxvirus Complement-Binding Protein,”Virus Research, 81:39-45 (2001).
Jacobs Bertram L.
Rich Alexander
Arizona Board of Regents
Hamilton Brook Smith & Reynolds P.C.
Massachusetts Institute of Technology
Mosher Mary E.
LandOfFree
Method of inhibiting pathogenicity of infectious agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of inhibiting pathogenicity of infectious agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of inhibiting pathogenicity of infectious agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3692236